U-Blot® Research Grade Emibetuzumab

Name: U-Blot® Research Grade Emibetuzumab
SKU: WA2780
Availability: InStock

$9,999.00

Size:50ug

SKU: WA2780-50

Catalog No.: WA2780

Specification: 50ug/100ug

Stock: In stock

U-Blot® Research Grade Emibetuzumab Learn more

Product details Specifications Q & A Education

U-Blot® Research Grade Emibetuzumab

Product Overview

Catalog No.: WA2780
SKU: WA2780-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: Tyrosine-protein kinase Met
Reactivity: Human
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Humanized
Isotype: IgG4-kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% purity as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Species: --
Gene ID-1: P08581
Uniprot: --
Background: Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic. • MET-dependent solid tumours - molecular diagnosis and targeted therapy., PMID:32514147 • ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence., PMID:27573171 • Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis., PMID:34848680 • The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance., PMID:30786811 • The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions., PMID:26822708 • MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas., PMID:34667077 • Targeting HGF/c-MET Axis in Pancreatic Cancer., PMID:33271944 • Targeting the hepatocyte growth factor/Met pathway in cancer., PMID:28673936 • Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases., PMID:30658428 • Hepatocyte growth factor in physiology and infectious diseases., PMID:28094206
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.